NASDAQ : MAZE
Maze Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 31.93 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.72B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.70B |
| Enterprise Value | 1.26B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 53.93M |
| Shares Outstanding | 53.93M |
| Shares Change (YoY) | +174.46% |
| Shares Change (QoQ) | +9.46% |
| Owned by Insiders (%) | 0.82% |
| Owned by Institutions (%) | 75.95% |
| Float | 35.18M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 84.89 |
| Forward PS | 376.35 |
| PB Ratio | 3.86 |
| P/TBV Ratio | 3.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 63.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 18.31 |
| Quick Ratio | 18.03 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -81.03 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -37.35% |
| Return on Assets (ROA) | -21.79% |
| Return on Invested Capital (ROIC) | -190.34% |
| Return on Capital Employed (ROCE) | -28.63% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $141,844 |
| Profits Per Employee | -$947,447 |
| Employee Count | 141 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | +0.70% |
| 50-Day Moving Average | 27.49 |
| 200-Day Moving Average | 31.85 |
| Relative Strength Index (RSI) | 63.25 |
| Average Volume (20 Days) | 782,227 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.53M |
| Short Previous Month | 6.57M |
| Short % of Shares Out | 13.96% |
| Short % of Float | 21.40% |
| Short Ratio (days to cover) | 8.28 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 20.00M |
| Gross Profit | 20.00M |
| Operating Income | -145.61M |
| Pretax Income | -133.59M |
| Net Income | -133.59M |
| EBITDA | -143.71M |
| EBIT | -145.61M |
| Loss Per Share | -$2.52 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 411.09M |
| Total Debt | 60.42M |
| Net Cash | 434.49M |
| Net Cash Per Share | $8.06 |
| Equity (Book Value) | 453.12M |
| Book Value Per Share | 8.16 |
| Working Capital | 397.46M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -106.54M |
| Capital Expenditures | -302,000 |
| Depreciation & Amortization | 1.91M |
| Net Borrowing | 39.40M |
| Free Cash Flow | -106.84M |
| FCF Per Share | -$1.98 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -728.06% |
| Pretax Margin | -667.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -174.46% |
| Shareholder Yield | n/a |
| Earnings Yield | -8.00% |
| FCF Yield | -6.29% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $62.54 |
| Price Target Difference | 98.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 9.75 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |